We are live on ! Find out more
ACRV icon

Acrivon Therapeutics
ACRV

63 hedge funds and large institutions have $140M invested in Acrivon Therapeutics in 2024 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 18 increasing their positions, 15 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 5

20% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 15

15% more funds holding

Funds holding: 55 → 63 (+8)

0.52% more ownership

Funds ownership: 74.18% → 74.71% (+0.52%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

13% less capital invested

Capital invested by funds: $161M → $140M (-$20.8M)

Holders
63
Holders Change
+8
Holders Change %
+14.55%
% of All Funds
0.83%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
13
Increased
18
Reduced
15
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.15M
2
Goldman Sachs
Goldman Sachs
New York
+$286K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$248K
4
UOC
UBS O'Connor
Illinois
+$171K
5
PFCS
Pale Fire Capital SE
Czech Republic
+$111K

Top Sellers

Rank Fund Capital Flow
1
Marshall Wace
Marshall Wace
United Kingdom
-$1.54M
2
EAM
Exome Asset Management
New York
-$817K
3
Millennium Management
Millennium Management
New York
-$278K
4
PCM
Prelude Capital Management
New York
-$264K
5
Citadel Advisors
Citadel Advisors
Florida
-$152K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIP
51
Ameritas Investment Partners
Nebraska
$4.18K – – –
GFM
52
GF Fund Management
China
$3.94K +$4.75K +654 New
RPA
53
Redwood Park Advisors
California
$3.01K +$3.63K +500 New
SCM
54
Sterling Capital Management
North Carolina
$2.41K +$2.65K +364 +984%
FDCDDQ
55
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.41K – – –
AB
56
Amalgamated Bank
New York
$2K – – –
Russell Investments Group
57
Russell Investments Group
United Kingdom
$1.34K -$254 -35 -14%
Nisa Investment Advisors
58
Nisa Investment Advisors
Missouri
$602 +$727 +100 New
SS
59
SBI Securities
Japan
$445 +$538 +74 New
GI
60
GAMMA Investing
California
$205 +$247 +34 New
RS
61
R Squared
Hong Kong
$120 +$145 +20 New
EAM
62
Exome Asset Management
New York
– -$817K -116,757 Closed
Millennium Management
63
Millennium Management
New York
– -$278K -39,750 Closed
PCM
64
Prelude Capital Management
New York
– -$264K -37,727 Closed
CPA
65
Capital Performance Advisors
California
– -$224 -32 Closed
Carson Wealth (CWM LLC)
66
Carson Wealth (CWM LLC)
Nebraska
– -$36 -5 -11%
1 2
3

ACRV Hedge Fund Activity: Q4 2024 in Review

63 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Acrivon Therapeutics (ACRV) for Q4 2024, worth a combined $140M — down 13% from $161M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new ACRV positions and 5 closed out — a net gain of 8 holders — while 18 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $1.15M. The largest seller was Marshall Wace, cutting an estimated $1.54M.

  • 63 institutional investors held Acrivon Therapeutics (ACRV) as of Q4 2024, up from 55 in Q3 2024.
  • Funds reported $140M of Acrivon Therapeutics stock for Q4 2024, down 13% quarter-over-quarter.
  • 13 funds opened new Acrivon Therapeutics positions in Q4 2024 and 5 closed out, a net change of +8 holders.
  • The largest Acrivon Therapeutics buyer in Q4 2024 was BlackRock, an estimated $1.15M added.
  • The largest Acrivon Therapeutics seller in Q4 2024 was Marshall Wace, an estimated $1.54M sold.

Based on aggregated 13F filings for Q4 2024.